Key result
Continuous infusion of atrial natriuretic peptide significantly reduced peritoneal thickness and suppressed fibrotic markers in a rat model of peritonitis-induced peritoneal fibrosis.
Why the study?
Does atrial natriuretic peptide ameliorate peritoneal fibrosis in a rat peritonitis model?
Population
Male Sprague-Dawley rats with peritonitis-induced peritoneal fibrosis model, and cultured peritoneal…
Comparison
Atrial natriuretic peptide continuous infusion… vs Vehicle continuous infusion via osmotic pump
Design
Preclinical, Peritoneal scraping performed in a blind manner
Follow-up
14 days
Authors
Loading...
Hypothesis-generating for ANP in peritoneal fibrosis prevention; leaves open translation and safety testing in human peritoneal dialysis.
Does atrial natriuretic peptide ameliorate peritoneal fibrosis in a rat peritonitis model?
Atrial natriuretic peptide may be useful in preventing inflammation-induced peritoneal fibrosis, as demonstrated in a rat model.
Kato et al. (2011) studied peritonitis-induced peritoneal fibrosis. Atrial natriuretic peptide (ANP) vs. vehicle (saline) was evaluated on peritoneal thickness and fibrotic markers. Continuous infusion of atrial natriuretic peptide significantly reduced peritoneal thickness and suppressed fibrotic markers in a rat model of peritonitis-induced peritoneal fibrosis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: